Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
How to prepare for the Fed's forthcoming interest rate cuts
Recommended
The sun now sets before 8 p.m. Will we ever do away with the time change?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
28.34
-0.07 (-0.25%)
Streaming Delayed Price
Updated: 1:56 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
5
6
Next >
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
August 16, 2024
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."
Via
Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Royalty Pharma Reports Second Quarter 2024 Results
August 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
July 24, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
NASDAQ:RPRX: good value for what you're paying.
April 24, 2024
Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
Royalty Pharma Declares Third Quarter 2024 Dividend
July 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
July 11, 2024
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
June 26, 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 12, 2024
Via
Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Via
InvestorPlace
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
June 03, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
May 28, 2024
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.
Via
Benzinga
Exposures
Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
May 28, 2024
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.
Via
Investor's Business Daily
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
May 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
May 23, 2024
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.
Via
Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024
From
Royalty Pharma plc; Cytokinetics
Via
GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
May 20, 2024
For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low.
Via
InvestorPlace
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
May 02, 2024
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses...
Via
Benzinga
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
April 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
April 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
3 Pharma Stocks to Sell in April Before They Crash & Burn
April 11, 2024
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
Via
InvestorPlace
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
April 09, 2024
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.
Via
InvestorPlace
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
April 09, 2024
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.